This inventor holds 5 USPTO granted patents. Top assignees: Scios Inc., Marion Merrell Dow Inc., Nova Pharmaceutical Corporation. Active years: 1991-2004.
Company Filing History:
2 out of 82 
1 out of 12 
1 out of 23 Years Active: 1991-2004
Title: The Innovative Contributions of Roger N. Hiner
Introduction
Roger N. Hiner, based in Baltimore, MD, has made significant strides in the field of peptide research and drug development. With a notable portfolio of five patents, he has been instrumental in the advancement of bradykinin antagonist peptides, showcasing his expertise and innovative mindset.
Latest Patents
Among Roger N. Hiner's latest inventions are two critical patents that focus on the modification of bradykinin peptides. The first patent details the substitution of L-Pro at the 7-position of bradykinin with a D-configuration hydroxyproline ether or thioether. This modification transforms bradykinin agonists into antagonists, with further refinements increasing enzyme resistance, potency, and specificity. These analogs are particularly valuable in treating conditions characterized by an excess of bradykinin, which can occur, for example, as a reaction to insect bites.
The second patent also centers around bradykinin, introducing substitutions at the 7- and 8-positions that convert bradykinin agonists into antagonists. This innovation enhances the efficacy of the peptides in clinical applications, especially for conditions involving heightened bradykinin levels.
Career Highlights
Roger has had a prolific career, with notable roles in companies such as Scios Inc. and Nova Pharmaceutical Corporation. His work in these organizations has laid the groundwork for his innovative contributions to the field of pharmacology and peptide chemistry.
Collaborations
Throughout his career, Hiner has collaborated with esteemed colleagues, including Donald J. Kyle and Waclaw J. Rzeszotarski. These partnerships have fostered a rich environment for innovation and development, leading to significant advancements in the understanding and application of bradykinin antagonists.
Conclusion
Roger N. Hiner's contributions to the field of peptide research are marked by a commitment to innovation and collaboration. With a focus on creating effective treatments for conditions related to bradykinin, his work continues to have a lasting impact on medical science and pharmacology. His research showcases the potential of well-crafted peptide analogs in addressing complex health issues, reaffirming the critical role of inventors in advancing healthcare solutions.